Ginkgo Bioworks Holdings, Inc.
DNA · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $227 | $251 | $478 | $314 |
| % Growth | -9.7% | -47.4% | 52.2% | – |
| Cost of Goods Sold | $39 | $54 | $204 | $130 |
| Gross Profit | $188 | $197 | $273 | $184 |
| % Margin | 83% | 78.5% | 57.3% | 58.7% |
| R&D Expenses | $424 | $581 | $1,053 | $1,150 |
| G&A Expenses | $246 | $385 | $1,430 | $863 |
| SG&A Expenses | $246 | $385 | $1,430 | $863 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $78 | $96 | $0 | $0 |
| Operating Expenses | $748 | $1,062 | $2,482 | $2,013 |
| Operating Income | -$560 | -$864 | -$2,209 | -$1,828 |
| % Margin | -246.5% | -343.8% | -462.4% | -582.6% |
| Other Income/Exp. Net | $12 | -$29 | $88 | -$10 |
| Pre-Tax Income | -$548 | -$893 | -$2,121 | -$1,838 |
| Tax Expense | -$0 | -$0 | -$15 | -$1 |
| Net Income | -$547 | -$893 | -$2,105 | -$1,830 |
| % Margin | -240.9% | -355.1% | -440.6% | -583.1% |
| EPS | -10.54 | -18.37 | -50.15 | -53.83 |
| % Growth | 42.6% | 63.4% | 6.8% | – |
| EPS Diluted | -10.54 | -18.4 | -50.2 | -55.53 |
| Weighted Avg Shares Out | 52 | 49 | 42 | 33 |
| Weighted Avg Shares Out Dil | 52 | 49 | 42 | 34 |
| Supplemental Information | – | – | – | – |
| Interest Income | $39 | $57 | $20 | $1 |
| Interest Expense | $0 | $0 | $0 | $2 |
| Depreciation & Amortization | $63 | $72 | $62 | $29 |
| EBITDA | -$484 | -$821 | -$2,060 | -$1,807 |
| % Margin | -213.3% | -326.6% | -431.2% | -575.7% |